Vaccines against Bacterial Respiratory Infections

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 257

Special Issue Editors

E-Mail Website
Guest Editor
Department of Infectious Disease, Imperial College London, London W2 1PG, UK
Interests: bacterial vaccines; pathogenicity; diagnostics; meningitis; tuberculosis

E-Mail Website
Guest Editor
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Interests: biological conjugation or PGCT; bacterial vaccines; streptococcus pneumoniae; pathogenesis

E-Mail Website
Guest Editor
Department of Infectious Disease, Imperial College London, London W2 1PG, UK
Interests: bacterial vaccines; pathogenesis; adaptive immunity; neisseria; streptococci; monoclonal antibodies

E-Mail Website
Guest Editor
Bristol Children's Vaccine Centre, University of Bristol, Bristol BS8 1TH, UK
Interests: respiratory infections; mucosal immunology; microbiology; transcriptomics; immune diagnostics; streptococci; tuberculosis

Special Issue Information

Dear Colleagues, 

Undoubtedly, the current COVID-19 pandemic has beamed a spotlight on respiratory infections and vaccines. While accruing data is showing a reduction in the incidence of bacterial respiratory infections during the pandemic owing to public health measures introduced to tackle COVID-19, these diseases remain a huge threat, and a resurgence can be expected as the pandemic subsides. Research into the development of vaccines—which have proven to be indispensable in the fight against these infections—must continue, but now with the significant incorporation of new strategies and technologies, some of which were instrumental in the rapid development of the COVID-19 vaccines. This Special Issue of Vaccines will highlight specific groundbreaking research covering all stages of the bacterial vaccine development process, from antigen discovery through assessments of immune responses in experimental human challenge models to the monitoring of impact and non-specific events. In this Issue, focus will also be preferentially given to those bacterial pathogens that cause human disease.

Prof. Dr. Paul Langford
Dr. Vanessa S. Terra
Dr. Fadil Bidmos
Dr. Alice Halliday
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • human respiratory infections
  • antigen discovery
  • immune responses
  • correlates of protection
  • experimental human challenge
  • mucosal vaccines
  • nucleic acid vaccines
  • animal models
  • social attitudes/vaccine surveillance

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop